SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for scientific trials, right this moment introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating remedies for neurodegenerative ailments. The outcomes have been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration targeted on remynd’s Part 2a scientific trial of REM127, an investigational, first-generation small molecule remedy concentrating on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The research enrolled a restricted variety of individuals and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the research by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin skilled on knowledge from greater than 26,000 individuals throughout landmark AD datasets corresponding to ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their scientific and biomarker trajectories underneath customary care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering a further layer of proof to assist interpret modifications noticed within the handled inhabitants. This strategy is especially helpful in early-phase research the place small pattern sizes restrict the power to attract conclusions utilizing conventional statistical strategies alone.
“It is a highly effective instance of how digital twins may also help unlock insights from small research,” stated Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to help smarter, quicker scientific analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering strategy in direction of attaining symptomatic reduction and illness modification in Alzheimer’s. It will help our efforts to advance an optimized second-generation remedy,” stated Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins supply a brand new lens for decoding biomarker developments over time—particularly in early-stage trials the place each knowledge level issues.”
For extra data, go to www.unlearn.ai or observe us on LinkedIn and X/Twitter.
